ESTRO 2024 - Abstract Book

S1796

Clinical - Lung

ESTRO 2024

showed pneumonitis grade ≥2, of which six were identified grade 2 (8.1%) and four grade 3 (5.4%) (vs. 9 (9%) patients with pneumonitis grade ≥2, four grade 2 and five grade 3, in STRIPE). There was no significant difference.

Conclusion:

By changing the radiation regime from 3X12.5Gy on the 60% isodose to 3 x 18.75 Gy prescribed on the median a higher dose could be applied to the PTV while maintaining similar lung parameters. However this has not translated into a significant improvement in outcome. The good effectiveness of SBRT in pulmonary lesions with a tolerable side effect profile was confirmed with the current irradiation regime. Further studies, especially prospective and larger ones, are necessary to determine the most effective radiation regimens.

Keywords: SBRT, NSCLC, dose

References:

1 Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Nestle U, Adebahr S, Kaier K, et al., Radiother Oncol. 2020 Jul;148:82-88. doi: 10.1016/j.radonc.2020.03.018. Epub 2020 Apr 6.

2988

Digital Poster

Surgery versus stereotactic radiotherapy in patients over 75 treated for stage IA-IIA NSCLC

Galdric Oliver 1 , Anne-Laure Couderc 2 , Mohamed Boucekine 3 , Audrey Zacchariotto 1 , Bertrand Kaeppelin 1 , Fourdrain Alex 4 , Pascal-Alexandre Thomas 4 , Laetitia Padovani 1 1 Assistance Publique-Hôpitaux de Marseille, Radiation Oncology, Marseille, France. 2 Assistance Publique-Hôpitaux de Marseille, Internal Medicine, Geriatric and Therapeutic, Marseille, France. 3 Assistance Publique-Hôpitaux de Marseille, Public Health Department Research, Marseille, France. 4 Assistance Publique-Hôpitaux de Marseille, Thoracic Surgery, Marseille, France

Purpose/Objective:

Lobectomy with lymph node dissection remains the standard treatment for IA-IIA NSCLC 1-2 .

Stereotactic ablative radiotherapy (SABR) is now a standard of care for inoperable early-stage non-small cell lung cancer (NSCLC) 3 . Its effectiveness, and noninvasiveness have led to make SABR a standard treatment for patients considered at high surgical risk.